Safeguarding animal life,
as if it were human life
To build relationships founded on mutual understanding with customers,
Fujita Pharmaceutical develops and supplies safe,
high-quality products that play a useful role for customers.
By discovering problems and devising and implementing solutions,
we foster the development of human resources that can bring innovation to our operations.
Customers are the foundation of the company.
The basis of the “quality first” philosophy is
creativity, hard work, and cooperation.
Don’t assume that conventional methods are
the best approach.
Fujita’s three principles
Valuing our core business
Over our many years of operations,
we’ve come to value a business that revolves around the domains of veterinary-use pharmaceutical development,
manufacturing, and sales.
Valuing the ability to execute effectively
We value the ability not only to discover problems and propose solutions,
but also to put those solutions into practice.
Better skills means higher pay.
We focus on developing employees’ skills and provide appropriate
compensation along with skill growth.
Nobuchika Fujita founds Fujita Company in the Osakimachi district of Tokyo (present-day Kamiosaki in Shinagawa-ku) and starts selling Cyclo (a drug for preventing sexually transmitted diseases), home medicines, and facial creams.
The mark of Fujita Company is visible in the imprint (on the left). It is likely that the company sold these products over a period of five years until it changed its name to Fujita Pharmaceutical Co., Ltd., in 1935.
Fujita Company changes its name to Fujita Pharmaceutical Co., Ltd., and Nobuchika Fujita becomes president.
Meguro Yakuhin Kogyo Co., Ltd., is founded to conduct drug research.
The company is absorbed by Shoko Yakuhin during World War II.
Meguro Yakuhin Kogyo starts synthesizing sulfamine.
The company changes its name from Shoko Yakuhin back to its original name (Fujita Pharmaceutical Co., Ltd.) and takes advantage of the Enterprise Reorganization Act to embark on a new chapter in its history.
The Head Office’s entryway in the late 1940s and early 1950s
The plank fence surrounding the company’s building evokes the look of the company as it was attempting to get back on its feet after the end of World War II. In 1950, a boom fueled by special demand from the Korean War was about to spark an abrupt recovery in the Japanese economy. Later, an 18-year period of high economic growth would begin in the mid 1950s.
Nihon Koryo Sangyo Co., Ltd., is founded to manufacture and sell synthetic adhesives as a follow-up product for sulfamine.
The company starts producing veterinary-use pharmaceuticals along with home medicines, taking a cue from a drug that had been used for military horses. The products were sold by the Livestock Division (Fujimoto Pharmaceutical Corporation) of Fujimoto Iryo Sangyo (present-day Pip Co., Ltd.).
New drug, home medicine, and veterinary drug catalog
A product catalog from around the time the company began manufacturing veterinary drugs during the decade starting in 1945. The company’s product line had grown to 54 items, and the product name Cyclo is used. The cover design is modern enough that it doesn’t look out of place today.
The company develops and starts selling Filarsen, an anti-filaria drug for dogs.
A product manufactured by Fujita Pharmaceutical and sold by Chuo Juiyaku Kizai Co., Ltd. Use of Filarsen, a poisonous substance, as the name for an injectable liquid for livestock and dogs evokes the tenor of the times.
Meguro Yakuhin Kogyo and Nihon Koryo Kogyo merge, and the new company changes its name to Nihon CMC Co., Ltd. Nobuchika Fujita becomes president.
The company focuses on the manufacture and sale of synthetic adhesives. It was around this time that Fujita Pharmaceutical began developing a series of veterinary-use pharmaceuticals.
The company begins selling Urajil, a fattening agent (synthetic hormone) for cattle.
The company develops and begins selling Haichul, an anthelmintic for treating lungworm drug for pigs; Nutress, a comprehensive nutrient supplement for livestock; and Nuparadine, an anthelmintic for treating roundworm in poultry.
Nutress, a comprehensive nutrient supplement for livestock, continues to be sold today.
The company develops and begins selling Torikokushi, a coccidiosis treatment for poultry, and Tonkey, an iron-deficiency anemia treatment.
Iron supplement to prevent anemia in pigs
The company develops and begins selling Linda, a long-acting sulfa drug.
Veterinary-use pharmaceuticals become the primary source of Fujita Pharmaceutical’s revenue by the 30th anniversary of its founding.
Long-acting sulfa drug
The Head Office’s entryway in 1959.
Nobuchika Fujita receives the Academia Prize from The Academic Society of Japan for his contributions to the livestock industry.
Academia Prize certificate
The company develops and begins selling Vanguard, a drug for preventing leucocytozoonosis in poultry.
Pamphlet about the prevention of leucocytozoonosis in poultry
Construction of the Tokyo Factory is completed in the city of Hachioji.
New factory in Hachioji
The factory’s appearance
The company absorbs Fujimoto Pharmaceutical, puts in place integrated structures that extend from manufacturing to sales, and changes its Japanese name slightly (remaining Fujita Pharmaceutical Co., Ltd., in English).
The Tokyo Factory adds an antibiotic manufacturing factory to its facility. The company develops and starts selling a treatment for mastitis.
The company convenes the inaugural general meeting of the Toyukai, its nationwide association of major dealers.
Inaugural general meeting of the Toyukai
The Tokyo Factory adds a large product warehouse. The company begins selling All Flex Ear Tags.
The company deploys IBM System 32 and launches an effort to streamline administrative workflows.
All Flex Ear Tags
In 2003, All Flex Ear Tags were selected as the designated ear tag for use with Japan’s system for providing identifying information for individual cattle (the cattle traceability system).
Two years earlier in September 2001, the government began requiring ear tags to be affixed to all cattle as an emergency measure for dealing with an outbreak of BSE. The company accommodated the order by fast-tracking manufacture of All Flex Ear Tags by 2003.
Completion of the Head Office building
Shinichi Fujita becomes presiden.
The Head Office building as completed in 1978
Sun Farm Co., Ltd., is established. The new company begins manufacturing and selling pig farming supplies.
The Tokyo Factory adds a tablet factory to its facility.
The company installs a high-frequency inductively coupled plasma (ICP) emission spectrometric analyzer to strengthen its research equipment.
The company absorbs Tokyo Pharmacochemistry Laboratory Co., Ltd., and works to enhance its line of drugs for racehorses.
The company enters into a development cooperation agreement with Mitsubishi Kasei Corporation.
Kazuhira Fujita becomes president.
The company jointly develops Guardian, a treatment for mastitis, with Dainippon Pharmaceutical Co., Ltd. (present-day Sumitomo Dainippon Pharma Co., Ltd.).
Mastitis treatment developed jointly with Dainippon Pharmaceutical (photograph shows current product, Guardian CL)
The company develops and begins selling Dobo Liquid, a thiamphenicol solution.
The company finishes installing a clean room for manufacturing GMP-compliant injectable drugs and increases the size of its mobile rack system-equipped warehouse.
The Tokyo Factory adds a powder factory with computer-controlled systems to its facility.
The company builds an internal network as part of an effort to streamline operations.
The Tokyo Factory adds an injectable drug factory next to its automated, computer-controlled warehouse.
The company deploys a laser printing system for ear tags.
The company deploys filling machines for syringes used to treat mastitis.
The company launches Cefazolin Inj., Fujita a cephalosporin drug.
The company launches its first-generation online B-to-B ordering system (OTO system) and website.
All Flex Ear Tags are chosen for use with Japan’s system for providing identifying information for individual cattle (the cattle traceability system).
The company launches Ivermectin Inj. Fujita (present-day Ivermec Inj.), an ivermectin drug for cattle and pigs.
The company launches Ivermectin PO (present-day Ivermec PO), an anthelmintic for treating endoparasites and ectoparasites in cattle.
The company launches its second-generation online B-to-B ordering system (OTO system).
The company launches Permethrin Emulsion, a pyrethroid insecticide.
The company launches Ivermectin Powder Fujita 0.04% (present-day Ivermec Powder 0.04%) and Ivermectin Powder Fujita 0.6% (present-day Ivermec Powder 0.6%), a pair of anthelmintics for treating endoparasites and ectoparasites in pigs.
Permethrin Emulsion Fujita
In an industry first, the company launches Fertirelin Inj. Fujita and Cloprostenol C reproductive hormone drugs for cattle in needle-tipped, pre-filled syringes.
Cloprostenol C and Fertirelin Inj. Fujita
The company launches Cyromazine Granules Fujita 2% and Cyromazine Liquid Fujita 10%, a pair of IGR insecticides.
Cyromazine Granules Fujita 2%
Cyromazine Liquid Fujita 10%
Construction of the Tokyo Factory’s Administrative Building is completed.
The company deploys an IP communication system as part of an effort to introduce new workstyles.
The company develops an individual livestock animal management system using compact IC tags.
Working with Sorun Corporation and Saxa Holdings, Inc., the company develops an RFID traceability system for pigs.
Construction of the Tokyo Factory’s Annex Building is completed.
Tokyo Factory’s Administrative Building
The Tokyo Factory, which was completed in 2006, as it appears today
The company launches Ivermec® PI (DSP), a drug for preventing heartworm and eliminating digestive nematodes in dogs, in a unique bone shape made from domestic Japanese beef (launched jointly with Sumitomo Dainippon Pharma Co., Ltd. and present-day DS Pharma Animal Health Co., Ltd.).
The company begins selling the Florfenicol series.
Masahiro Fujita becomes president.
The company deploys ERP, a new centralized back-end system, across the entire company under the name “Field 80.”
The company launches MyFreeGuard® for Dogs and MyFreeGuard® for Cats, a pair of domestically manufactured flea and tick repellents (launched jointly with Kyoritsu Seiyaku Corporation).
The company launches MilbemycinTab Fujita, a drug for preventing heartworm and eliminating digestive nematodes in dogs, as a small, chewable tablet that is highly palatable.
The company begins airing a television commercial to take a step toward increasing its corporate value and strengthening its brand. The commercial features Bazooka, a skateboard-riding bulldog, and communicates the company’s slogan of “Safeguarding animal life, as if it were human life.”
The company holds a ceremony to commemorate the 80th anniversary of its founding.
Yamaichi Yakuhin Sangyo co., Ltd., transfers its Kuroiso Factory to the company.
The Kuroiso Factory
The company launches Flunixin Inj. Fujita, an NSAIDS drug for cattle and horses (launched jointly with ASKA Pharmaceutical Co., Ltd., [present-day ASKA Animal Health Co., Ltd.]).
The company begins supplying Moxiheart Tab KS, a drug for preventing heartworm and eliminating digestive nematodes in dogs, to Kyoritsu Seiyaku Corporation in the form of a small, chewable tablet that is highly palatable.
Flunixin Inj. 10% Fujita
The company begins supplying Medetomin Injection Meiji and Mepatia Injection Meiji, a pair of sedatives and painkillers for dogs and cats, to Meiji Seika Pharma Co., Ltd.
The company launches Flumethol®, a pyrethroid drug for treating ectoparasites in cattle; Enroflox® Inj. 10%, an enrofloxacin injection; and Tilmicosin Inj. 300 Fujita and Tilmicosin Powder 20 Fujita, a pair of tilmicosin drugs.
Enroflox® Inj. 10%
The company renovates its Kuroiso Factory and begins manufacturing a series of major injectable drugs, including Ivermec Inj. and Florfenicol Inj.
Tilmicosin Inj. 300 Fujita
Tilmicosin Powder 20 Fujita
The company updates its website and introduces Fuppy, its mascot character.
Official Mascot Character Fuppy
The company launches Early Start®, a formula feed containing protein and vitamins for piglets.
The company deploys smart factory technology.
We’re minimizing human error and maintaining high-quality manufacturing structures by automating manufacturing processes and introducing systems that utilize smart devices throughout operations ranging from raw material acceptance to manufacturing and product shipment.
The company launches Bovine Coccitol®15% and Porcine Coccitol® 10%, a pair of toltrazuril and antiprotozoan drugs for cattle and pigs, respectively.
Bovine Coccitol® 15%
Vendée Globe, the first single-handed, non-stop, around-the-world yacht race in which an Asian competed
Sponsorship agreement with Kojiro Shiraishi, an ocean adventurer
The company launches Meloxirin Chewables, the first canine NSAIDs anti-inflammation and painkiller drug to be sold as a chewable product made from beef.
The company begins supplying Moxiheart® Chewables, a drug for preventing heartworm and eliminating digestive nematodes in dogs that is packaged as a chewable, highly palatable product made from beef, to Virbac Japan.
The company begins selling MyFreeGuard® and MyFreeGuard® a, a pair of domestically manufactured flea and tick repellents, to DS Pharma Animal Health Co., Ltd.
The company begins selling Canine-Filaria-Kit, a kit for diagnosing heartworm in dogs.
The company launches Meloxirin® Inj. 5%, an anti-inflammation and painkiller drug for cattle.
Meloxirin® Inj. 5%
The company launches TSU Liquid/TSU Dry and TST Liquid/TST Dry, a pair of ear sampling kits.
TSU Liquid/TSU Dry
TST Liquid/TST Dry
The company opens a new warehouse at its Tokyo Factory.
The company begins supplying MP+, a long-lasting ACE inhibitor OneHeart® tablet for chronic heart failure in dogs and chronic kidney failure in cats, to MP Agro Co., Ltd.
MP+, a long-lasting ACE inhibitor OneHeart® tablet for chronic heart failure in dogs and chronic kidney failure in cats
The company enters into a sponsorship agreement for the DMGMORI Sailing Team, for which ocean adventurer Kojiro Shiraishi will compete in the Vendée Globe, a single-handed, non-stop, around-the-world yacht race, as skipper